Forest Laboratories and Nabriva Therapeutics Sign Agreement
June 01 2012 - 8:00AM
Business Wire
Forest Laboratories, Inc. (NYSE: FRX), an international
pharmaceutical manufacturer and marketer, and Nabriva Therapeutics
announced today that they have entered into an agreement for the
development of Nabriva’s novel antibacterial agent, BC-3781.
Pursuant to the agreement, Forest will provide Nabriva with $25
million, and fund and conduct in collaboration with Nabriva,
certain development activities related to BC-3781 over the next 12
months. During the 12-month period, Forest has the exclusive right
to acquire Nabriva. Forest's decision to acquire Nabriva will be
dependent upon certain contingencies. No further financial or other
terms were disclosed. The transaction is subject to customary
regulatory clearances including termination of the applicable
Hart-Scott-Rodino waiting period.
About BC-3781
BC-3781 belongs to a novel class of antibiotics, the
pleuromutilins. BC-3781 exhibits microbiological activity against a
wide range of Gram-positive pathogens (including
Methicillin-Resistant Staphylococcus aureus or MRSA and
penicillin-resistant Streptococcus pneumoniae) as well as certain
Gram-negative organisms (including Legionella pneumophila and
Chlamydophila pneumoniae), often implicated in respiratory
infections. In addition, studies to date suggest BC-3781 exhibits
no cross resistance with other antibiotic classes and has a low
propensity for inducing resistance itself. Based on its profile,
BC-3781 may have utility in the treatment of both Acute Bacterial
Skin and Skin Structure Infections (“ABSSSI”) and Community
Acquired Bacterial Pneumonia, among other conditions. BC-3781 would
complement Forest’s existing hospital antibiotic franchise because
intravenous and oral forms are expected, providing an opportunity
to treat patients after they are discharged from a hospital. In
2011, Nabriva announced positive results from a Phase 2b study of
BC-3781 in 207 patients with ABSSSI and the parties expect to
advance BC-3781 into pivotal Phase 3 studies in 2013.
About Nabriva Therapeutics
Nabriva Therapeutics is a biotechnology company focused on
developing a new class of antibiotics for the treatment of serious
infections caused by resistant pathogens. Nabriva’s lead systemic
product, BC-3781, is being developed for the treatment of serious
skin infections and bacterial pneumonia caused by S. aureus, S.
pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, L.
pneumophila and other bacteria, including drug resistant strains
such as MRSA and Vancomycin resistant Enterococcus faecium. Nabriva
Therapeutics has a proven track record in world-class medicinal
chemistry, clinical expertise, a seasoned management team and solid
IP.
About Forest Laboratories
Forest Laboratories' (NYSE: FRX) longstanding global
partnerships and track record developing and marketing
pharmaceutical products in the United States have yielded its
well-established central nervous system and cardiovascular
franchises and innovations in anti-infective, respiratory,
gastrointestinal and pain management medicine. Forest’s pipeline,
the most robust in its history, includes product candidates in all
stages of development across a wide range of therapeutic areas. The
Company is headquartered in New York, NY. To learn more, visit
www.FRX.com.
Except for the historical information contained herein, this
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
statements involve a number of risks and uncertainties, including
the difficulty of predicting FDA approvals, the acceptance and
demand for new pharmaceutical products, the impact of competitive
products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and any subsequent SEC filings.
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Oct 2023 to Oct 2024